Home Newsfeeds Fed’s Bostic Says Inflation ‘Too High’, Have To Get ‘Under Control’

Fed’s Bostic Says Inflation ‘Too High’, Have To Get ‘Under Control’

-Bloomberg

byBenzinga Newsdesk

October 18, 2022

1 minute read

-Bloomberg

Leafly Holdings Q3 EPS $0.28 Up From $(0.18) YoY, Sales $11.78M Up From $10.90M YoY

By Benzinga Newsdesk

November 10, 5:32 PM

Leafly Holdings (NASDAQ:LFLY) reported quarterly earnings of $0.28 per share. This is a 255.56 percent increase over losses of $(0.18) per share from the same period last year. The company reported $11.78 million in

LFLY

RSV Vaccines from Pfizer and GSK Gain CDC Advisory Committee’s Favor for Older Adults

By Vandana Singh

June 22, 8:56 AM

The US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines from Pfizer Inc (NYSE: PFE) and GSK plc (NYSE:

GSK

AEON Biopharma Announces Strategic Resource Reprioritization And Cost Reduction Plan; AEON Has Reduced Its Workforce By ~55%

By Benzinga Newsdesk

May 29, 8:17 AM

AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical

AEON

Innocan Pharma Secures $1.4M Via Private Placement

By Vuk Zdinjak

August 4, 7:30 AM

Innocan Pharma Corporation (OTC: INNPF) (CSE:INNO) (FSE:IP4) has closed a non-brokered private placement offering of 8.4 million units of Innocan at a price of CA$0.23 per unit

CSE:INNO

Fed’s Bostic Says Inflation ‘Too High’, Have To Get ‘Under Control’

Related Posts

Leafly Holdings Q3 EPS $0.28 Up From $(0.18) YoY, Sales $11.78M Up From $10.90M YoY

RSV Vaccines from Pfizer and GSK Gain CDC Advisory Committee’s Favor for Older Adults

AEON Biopharma Announces Strategic Resource Reprioritization And Cost Reduction Plan; AEON Has Reduced Its Workforce By ~55%

Innocan Pharma Secures $1.4M Via Private Placement